NUCL 1 |
| The application of imaging to drug development as a tool for timely and rational decision making has gained interest in recent years. The majority of literature examples to date have focused on brain receptor occupancy studies; knowledge that target plasma concentrations correspond to the desired central receptor occupancy can guide dose selection, or justify a “no go” decision, for phase 2. While this application is extremely useful, there are many other therapeutic areas and imaging paradigms that can significantly impact drug development. For example, the surge of molecular based targets for cancer therapy will greatly benefit from molecular imaging based approaches to better define mechanism of action and ultimately predict clinical benefit to patients. One of the key challenges to using imaging in these types of paradigms is the need for robust techniques and protocols that can reliably assess longitudinal change, both within subjects and between groups of subjects at different sites. The presentation will address these issues using examples from the Pfizer portfolio. |
|
Molecular Imaging
9:00 AM-11:50 AM, Sunday, August 19, 2007 Boston Park Plaza -- Stuart Rm, Oral
Division of Nuclear Chemistry & Technology |